VentriPoint Diagnostics Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Hugh MacNaught
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 18 Hook Avenue Toronto ON Canada M6P 1T4
- IPO Date
- Sep 22, 2010
- Website
- ventripoint.com
- Similar Companies
- Business
- Ventripoint Diagnostics Ltd. is a medical technology company specializing in advanced AI-powered cardiac imaging solutions designed to enhance heart health diagnostics and patient care globally. Founded with the mission to improve imaging for congenital heart defect patients, Ventripoint offers its proprietary VMS+ system, which uses patented Knowledge Based Reconstruction technology to convert 2D echocardiograms into precise 3D models of all four heart chambers, delivering volumetric cardiac measurements comparable in accuracy to MRI at substantially lower cost and time. The company’s core products include the VMS+ software suite for 3D echocardiography and MRI, which provides accurate volumetric data and ejection fraction metrics, compatible with ultrasound systems from various vendors. Ventripoint serves hospitals and cardiac centers predominantly in North America, Europe, and the U.K., targeting pediatric and adult congenital heart disease diagnostics as well as broader cardiology applications requiring precise right ventricle assessment. In recent developments, Ventripoint has expanded its strategic partnerships and commercial footprint. Key collaborations include an ongoing integration of its VMS+ 3D capabilities with ASCEND Cardiovascular’s diagnostic viewer and reporting applications, creating an end-to-end cardiology workflow solution that enhances diagnosis and monitoring of fetal, pediatric, and adult congenital heart disease. Additionally, the company has entered into a collaboration with Providence Health Care Ventures to validate the VMS+ platform at St. Paul’s Hospital in Vancouver, broadening clinical validation and supporting commercialization in both tertiary and remote healthcare settings. In 2025, Ventripoint also extended its partnership with Angiopro GmbH, its exclusive distributor in the DACH region, which has progressed to an investment relationship, signaling increased market commitment in Europe. The company received FDA 510(k) clearance for its VMS+ 4.0 software update, featuring automation improvements and magnet-free sensor technology, which have enhanced product quality, manufacturing scale, and clinical workflow integration. Ventripoint is advancing its commercialization strategy with ongoing quality audits, manufacturing scale-up, and efforts to secure growth capital to support continued innovation and market expansion. Overall, Ventripoint Diagnostics operates within the medical technology and cardiovascular diagnostics industry, focusing on AI-enhanced echocardiographic imaging. Headquartered in Toronto, Canada, the company targets healthcare providers such as hospitals, pediatric cardiac centers, and cardiologists, addressing unmet needs for accurate, accessible, and efficient cardiac imaging. Its product portfolio centers on the VMS+ software platform and related AI and sensor technologies, which are validated through extensive clinical research and multiple publications. Ventripoint continues to leverage strategic partnerships, A.I. innovation, and regulatory approvals to strengthen its position as a market leader in congenital and general cardiology diagnostics worldwide.
Company News
UniDoc Health Signs MOU with Ventripoint Diagnostics to Evaluate Remote Cardiac Assessment and Screening Platform
Ventripoint Expands Subscription Access for FDA-Cleared AI Cardiac Imaging
Ventripoint Diagnostics Announces Cancellation and Re-Grant of Options, Grant of Annual Incentive Options and Private Placement
UniDoc Health and Ventripoint Diagnostics Sign MOU to Evaluate Scalable Remote Cardiac Assessment and Screening Platform
Ventripoint Strengthens Board with Appointment of MedTech Executive and Commercialization Leader Dr. Philip Toleikis
Ventripoint Issue Shares for Payment of Debenture Interest
Ventripoint Engages More Capital Ltd.
Ventripoint Diagnostics' VMS+ Technology Selected for World-First AI Cardiac Monitoring Study in Breast Cancer Patients
Ventripoint and Ollie Hinkle Heart Foundation Partner to Expand Access to AI-Powered Heart Imaging for Children Living with Heart Disease
Ventripoint Diagnostics Announces Support for the Global Congenital Heart Disease Alliance
Ventripoint Diagnostics Ltd. (VPT:CA) Shareholder/Analyst Call Transcript
Ventripoint Provides Videoconference Link to Annual General Meeting and Corporate Update
Ventripoint Announces Closing of $308,030 Non-Brokered Units Private Placement
Ventripoint Issues Shares for Payment of Debenture Interest
The $59B Quiet Shift Reshaping How Patients Access Care
Ventripoint to Exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology
Ventripoint's VMS+ (TM) 4.0 Submitted for Regulatory Approval in China by Lishman Global Inc.
Ventripoint Issue Shares for Payment of Debenture Interest
Ventripoint's VMS+(TM) 4.0 Recognized with Gold Edison Award, Validating Leadership and Future Potential
Ventripoint Diagnostics Announces Collaboration with the Health Division of the Montecristo Group